Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Active Treatment in Type 2 Diabetes With NASH
NCT04639414Phase 4Completed
- Sponsor
- German Diabetes Center
- Start
- Mar 2021
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Combined treatment with Empagliflozin and Semaglutide, Empagliflozin monotherapy and Placebo (3 arms). Primary endpoint: Histological resolution of NASH without worsening of fibrosis at 48 weeks. Started Mar 2021; status: completed.
02
Drugs
empagliflozinsemaglutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04639414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639414.